IRIS
SOTO PARRA, HECTOR
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.021
AS - Asia 1.479
EU - Europa 1.172
SA - Sud America 366
AF - Africa 107
OC - Oceania 5
Totale 6.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.964
SG - Singapore 1.031
RU - Federazione Russa 421
BR - Brasile 322
IE - Irlanda 320
CN - Cina 224
IT - Italia 103
BE - Belgio 92
VN - Vietnam 66
CI - Costa d'Avorio 50
DE - Germania 37
IN - India 35
UA - Ucraina 35
CA - Canada 34
GB - Regno Unito 31
FR - Francia 27
NG - Nigeria 23
AT - Austria 19
HK - Hong Kong 19
KR - Corea 19
IR - Iran 14
MX - Messico 13
PL - Polonia 13
AR - Argentina 11
FI - Finlandia 11
ID - Indonesia 10
IQ - Iraq 10
NL - Olanda 10
SE - Svezia 10
TR - Turchia 9
EC - Ecuador 8
BG - Bulgaria 7
CH - Svizzera 7
UZ - Uzbekistan 7
VE - Venezuela 7
BJ - Benin 6
EG - Egitto 6
MA - Marocco 6
PE - Perù 6
BD - Bangladesh 5
ES - Italia 5
JP - Giappone 5
SN - Senegal 5
CO - Colombia 4
KE - Kenya 4
LB - Libano 4
LT - Lituania 4
ZA - Sudafrica 4
CL - Cile 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
UY - Uruguay 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
DK - Danimarca 2
HU - Ungheria 2
KZ - Kazakistan 2
NI - Nicaragua 2
NO - Norvegia 2
PA - Panama 2
PH - Filippine 2
PK - Pakistan 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
BT - Bhutan 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GL - Groenlandia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MD - Moldavia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 6.150
Salva come PNG Salva come JPEG
Città #
Santa Clara 677
Singapore 533
Dallas 433
Chandler 343
Dublin 315
Chicago 213
Moscow 156
Boardman 118
Beijing 100
Ashburn 93
Brussels 92
Cambridge 88
Lawrence 88
Andover 83
Des Moines 59
Abidjan 50
Los Angeles 47
Catania 39
The Dalles 37
Ho Chi Minh City 35
Hefei 34
São Paulo 32
Columbus 28
Houston 27
Wilmington 27
Buffalo 23
Abuja 22
Bremen 22
Jacksonville 22
Hong Kong 19
Seoul 19
Saint Petersburg 17
Civitanova Marche 12
Rio de Janeiro 12
Leawood 11
Toronto 11
Falls Church 10
Kochi 10
Lappeenranta 10
Council Bluffs 9
Hanoi 9
New York 9
Ottawa 9
Warsaw 9
Orem 8
Curitiba 7
Milan 7
Montreal 7
Mumbai 7
Ardabil 6
Cotonou 6
Guarulhos 6
Mexico City 6
Nuremberg 6
Pune 6
Redondo Beach 6
Rome 6
San Mateo 6
Seattle 6
Stockholm 6
Amsterdam 5
Baghdad 5
Brooklyn 5
Campinas 5
Dakar 5
Nanjing 5
Porto Alegre 5
San Jose 5
Shenyang 5
Sofia 5
Vienna 5
Aci Catena 4
Atlanta 4
Bauru 4
Belo Horizonte 4
Boston 4
Brasília 4
Bussero 4
Cairo 4
Istanbul 4
Jakarta 4
Lima 4
Phoenix 4
Poplar 4
Tappahannock 4
Thái Bình 4
Aracaju 3
Augusta 3
Caruaru 3
Da Nang 3
Edinburgh 3
Goiânia 3
Guayaquil 3
Hortolândia 3
London 3
Manaus 3
Nairobi 3
Portland 3
Poços de Caldas 3
Quito 3
Totale 4.271
Salva come PNG Salva come JPEG
Nome #
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC 127
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 109
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles 106
Benign form of Myasthenia Gravis after Nivolumab treatment 102
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: Preliminary experience 102
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: A retrospective Italian study 101
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 100
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma 99
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer 98
Direct Left Ventricular Metastasis Reduction: 3D-Echo Monitoring For Management of Clinical Case 97
Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer 93
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 93
Benign form of myasthenia gravis after nivolumab treatment 91
Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP) 91
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients 89
Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L 89
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 87
Nutritional support in patients with cancer of the esophagus: Impact on nutritional status, patient compliance to therapy, and survival 87
Bladder Cancer 86
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome 85
Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases 84
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study 82
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S 82
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions 80
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: Initial experience 75
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial 74
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) 73
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 73
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer 72
Pre-operative hyperfractionated radiotherapy and 5-Fluorouracil continuous infusion in elderly patients with locally advanced primary rectal cancer (LA-PRC): feasibility, pathologic complete response, sphincter preservation and local control 72
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma 71
Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease 70
Treatment perspectives in advanced non-small cell lung cancer 68
Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma 68
Malignant pleural mesothelioma: The gemcitabine-vinorelbine combination in pemetrexed-pretreated patients 67
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 67
Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy 66
Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study 66
First-line lorlatinib or crizotinib in advanced alk-positive lung cancer 66
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 66
Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato 65
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer 64
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 64
Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour 64
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 64
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 64
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 64
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer 63
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 63
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study 63
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study 63
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC 62
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 62
Histology-based combination induction chemotherapy for elderly patients with clinical stage III non-small cell lung cancer 62
Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study 62
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma 61
Extensive experience of disease control with gefitinib and the role of prognostic markers 61
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 61
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer 60
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients 60
Lessons from the ‘iressa’ expanded access programme: Gefitinib in special non-small-cell lung cancer patient populations 59
Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy 59
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies? 58
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 57
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 56
Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study 56
Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria 56
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC 56
Palbociclib in hormone-receptor-positive advanced breast cancer 55
Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma 55
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: A retrospective analysis 55
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study 54
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 53
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study 53
The evolution of surgery in non-small cell lung cancer 52
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 51
Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer 51
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer 51
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus 51
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 50
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: A whatsapp messenger-based report from the Italian college of chief medical oncologists 49
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 49
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial 48
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 48
The impact of the SARS-CoV-2 outbreak on the psychological flexibility and behaviour of cancelling medical appointments of italian patients with pre-existing medical condition: The “impact-COVID-19 for patients” multi-centre observational study 47
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer 47
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 47
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 46
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 46
Soft tissue and bone sarcomas 43
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 42
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial 42
Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study 39
Totale 6.307
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.720
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.720
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202156 0 0 0 0 0 0 7 2 3 0 44 0
2021/2022458 9 54 0 2 58 51 85 23 19 1 38 118
2022/20231.096 94 16 25 133 85 207 3 171 263 5 52 42
2023/2024363 23 131 8 9 9 56 11 20 0 2 55 39
2024/20252.155 42 325 93 76 520 318 44 88 154 280 135 80
2025/20261.906 188 98 492 178 620 330 0 0 0 0 0 0
Totale 6.307